Oct 15, 2024
Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024
Oct 10, 2024
Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa
Sep 19, 2024
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
Sep 16, 2024
Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona
Sep 09, 2024
Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon
Aug 08, 2024
Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Jul 10, 2024
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Jun 18, 2024
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect
May 29, 2024
Nanoscope Therapeutics to Present at the BIO International Convention
May 02, 2024
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
Apr 29, 2024
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
Apr 25, 2024
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
Feb 21, 2024
Nanoscope Therapeutics Announces Participation in Upcoming Conferences
Feb 14, 2024
Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit
Jan 18, 2024
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa
Jan 12, 2024
Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference
Feb 02, 2021
Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health
Jan 25, 2021
Nanoscope Therapeutics Receives Orphan Drug Designation for gene therapy of blindness